Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Dauntless who wrote (3261)	4/1/1998 2:14:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 7041

Dauntless, the FDA could approved Vasomax for the 3% blue vision group of viagra users. This 3% could go higher because viagra once in the whole population will show even double this number, side effects increases when drugs go out to the real world. Also, the longer time amd more frequent use in the real world will increase the side effects. In the other side of the equation, the other side effects expected from vasodilation (both viagra and vasomax are vasodilators via different mechanisms) will be similar: headache, nasal stuffiness, hypotension, in this groups vasomax could or could not give the same side effects. But, the blue visual changes are very specific of viagra.